A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine



Francis, Jose, Zvada, Simbarashe P, Denti, Paolo, Hatherill, Mark, Charalambous, Salome, Mungofa, Stanley, Dawson, Rodney, Dorman, Susan, Gupte, Nikhil, Wiesner, Lubbe
et al (show 6 more authors) (2019) A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 63 (4).

[img] Text
A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine.pdf - Published Version

Download (693kB) | Preview
Item Type: Article
Uncontrolled Keywords: AADAC, SLCO1B1, pharmacogenetics, population pharmacokinetics, rifapentine, tuberculosis
Depositing User: Symplectic Admin
Date Deposited: 29 May 2019 09:50
Last Modified: 13 Jan 2021 18:11
DOI: 10.1128/AAC.01964-18
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3043507